Text version
Hi! David Rosenberg here for the Psychopharmacology Institute. In this Child and Adolescent Psychiatry Smart Take, we will examine a new treatment alternative for reducing tics in children and adolescents with Tourette syndrome. Many of you know that nonmedication therapies, such as cognitive–behavioral therapy and habit reversal, are sufficient for Tourette syndrome and tic disorders, which often dissipate or even go away in adulthood. However, some persist and can be highly debilitating. Unfortunately, we have limited medication interventions for children and adolescents with tic disorders. Currently, there are only 3 FDA-approved medications for Tourette syndrome—haloperidol, pimozide, and aripiprazole.
Moreover, these medicines have safety concerns, particularly tardive dyskinesia, parkinsonism, neuroleptic malignant syndrome, and metabolic complications. Some non-FDA–approved medications treat Tourette syndrome, including guanfacine, immediate and extended release, or clonidine. Some of us have used clonazepam or other atypical antipsychotics, but it is clear that there is a need for new and
Unlock this CAP Smart Take and earn 0.50 CMEs
Become a Silver, Gold, Silver extended or Gold extended Member.
Already have an account? Sign in
